You are here: Industry Insights > COVID-19

News List

Novel thermally-stable COVID-19 vaccine capsule developed europeanpharmaceuticalreview
March 20, 2020
Developers have announced that they are ready to manufacture and formulate an innovative novel coronavirus vaccine capsule.
EMA issues statement on ibuprofen reports relating to COVID-19 europeanpharmaceuticalreview
March 20, 2020
The EMA has announced that reports of NSAIDs like ibuprofen making the COVID-19 coronavirus worse have no scientific basis.
USP Offers Support for COVID-19 Antiviral/Vax Developers contractpharma
March 20, 2020
Aims to help developers ensure quality of their materials as they scale up manufacturing to bring products into clinical development.
U.S. HHS Seeks Stakeholder COVID-19 Countermeasures contractpharma
March 20, 2020
The U.S. Department of Health & Human Services is providing a portal for the COVID-19 medical countermeasures task force ...
Industrial Layout Analysis of the New Candidate Drug Against COVID-19: Sivelestat Sodium PharmaSources/Zhulikou431
March 20, 2020
The NMPA has so far urgently approved the clinical trials of 5 products against the COVID-19 to better prevent and control it, including sivelestat sodium hydrate, favipiravir, remdesivir, and BDB-001 injection, etc.
Emergent BioSolutions and Vaxart partner on oral coronavirus vaccine pharmaceutical-technology
March 20, 2020
Emergent BioSolutions has agreed to provide molecule-to-market contract development and manufacturing (CDMO) services for Vaxart’s oral vaccine candidate against Covid-19 coronavirus infection.
Roche to start Phase III trial of Actemra in Covid-19 patients pharmaceutical-technology
March 20, 2020
Roche has collaborated with the US Food and Drug Administration (FDA) to conduct a Phase III clinical trial of Actemra/RoActemra (tocilizumab) in hospitalised adults with severe Covid-19 pneumonia.
Roivant, Mateon to develop Covid-19 drug candidates pharmaceutical-technology
March 20, 2020
Roivant Sciences is in discussion with the US, Europe and Asian regulators to develop gimsilumab for treating acute respiratory distress syndrome (ARDS) caused by Covid-19.
CanSinoBIO, Synairgen get regulatory approval for Covid-19 trials pharmaceutical-technology
March 20, 2020
China-based CanSino Biologics has received regulatory approval to conduct Phase I clinical trial of recombinant novel coronavirus vaccine (adenovirus type 5 vector) candidate.
AbbVie’s HIV drug combo shows no benefit in Covid-19 trial pharmaceutical-technology
March 20, 2020
A clinical trial in Covid-19 patients in China has yielded no therapeutic benefits with AbbVie’s HIV drug combination of lopinavir and ritonavir, marketed as Kaletra.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 437 438 Next page